Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.

Ananworanich J, Melvin D, Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM; PENTA 11 Study Group.

AIDS. 2016 Apr 24;30(7):1075-81. doi: 10.1097/QAD.0000000000001011.

PMID:
26730569
2.

The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team.

PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013.

3.

Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.

Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA 11 Extension Study Group.

AIDS. 2013 Feb 20;27(4):579-89. doi: 10.1097/QAD.0b013e32835c1181.

PMID:
23135172
4.

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group.

PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.

5.

Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.

Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team.

AIDS Behav. 2013 Jan;17(1):193-202. doi: 10.1007/s10461-012-0197-y.

6.

Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.

Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.

PMID:
22293548
7.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

8.

Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.

Cressey TR, Urien S, Hirt D, Halue G, Techapornroong M, Bowonwatanuwong C, Leenasirimakul P, Treluyer JM, Jourdain G, Lallemant M; PHPT-3 Team.

Ther Drug Monit. 2011 Feb;33(1):25-31. doi: 10.1097/FTD.0b013e3182057f6f.

9.

Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study.

Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, Sriminiphant S, Technakunakorn P, Ngo-Giang-Huong N, Duong T, Le Coeur S, Jaffar S, Lallemant M; Program for HIV Prevention and Treatment Study Team.

Clin Infect Dis. 2010 Dec 15;51(12):1449-57. doi: 10.1086/657401. Epub 2010 Nov 5.

10.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team.

AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

11.

Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, Collins IJ, Jarupanich T, Sukhumanant T, Achalapong J, Sabsanong P, Chotivanich N, Winiyakul N, Ariyadej S, Kanjanasing A, Ratanakosol J, Hemvuttiphan J, Kengsakul K, Wannapira W, Sittipiyasakul V, Pornkitprasarn W, Liampongsabuddhi P, McIntosh K, Van Dyke RB, Frenkel LM, Koetsawang S, Le Coeur S, Kanchana S; PHPT-4 Study Team.

Clin Infect Dis. 2010 Mar 15;50(6):898-908. doi: 10.1086/650745.

12.

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS.

AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.

PMID:
20010073
13.

Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.

Pornprasert S, Mary JY, Faye A, Leechanachai P, Limtrakul A, Rugpao S, Sirivatanapa P, Gomuthbutra V, Matanasaravoot W, Le Coeur S, Lallemant M, Barré-Sinoussi F, Menu E, Ngo-Giang-Huong N; ANRS 1267 study team and HIV-1 PMTCT-PlaNet.

Curr HIV Res. 2009 Mar;7(2):211-7.

PMID:
19275589
14.

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group.

Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657.

Supplemental Content

Loading ...
Support Center